Basic Information

Strain Name
C57BL/6-Tigittm1(TIGIT)Bcgen/Bcgen
Stock Number
110017
Common Name
B-hTIGIT Mice
Source/Investigator
Bcgen (Beijing Biocytogen Co., Ltd)
Related Genes
Tigit (T cell immunoreceptor with Ig and ITIM domains)
Species
C57BL/6
Appearance
Black
Genotypes
Homozygous

Description

TIGIT (T-cell immunoreceptor with Ig and ITIM domains), a member of the immunoglobulin family of PVR (poliovirus receptor), is a type I transmembrane protein. Similar to PD-1, TIM3, and LAG3, TIGIT is highly expressed in cancer tissues and competitively binds to TIGIT receptors, which can interact with DNAM-1 on the surface of NK cells to reduce the NK cell killing efficiency of cancer cells. Therefore, anti-TIGIT antibody can enhance NK cell ability to destroy tumor cells by facilitating DNAM-1 binding to TIGIT receptors. TIGIT thus has become a new generation target for cancer immunotherapy.

Targeting Strategy

Details

Phenotype

mRNA Expression Analysis

B-hTIGIT-Mice-details-mrna-expression-analysis

 

 

 

 

RT-PCR analysis of TIGIT mRNA expression. The hTIGIT, but not mTIGIT, mRNA was detectable in splenocytes of the homozygous B-hTIGIT mice.

Protein Expression Analysis

 

Splenocytes from both wild type (WT)C57BL/6 and homozygous B-hTIGIT mice were analyzed by flow cytometry.mTIGIT+ cells were detectable in the WT mice, while hTIGIT+ cells were detectable in the homozygous B-hTIGIT mice.

Application

TIGIT Ab Efficacy Evaluation

B-hTIGIT-Mice-details-tigit-ab-efficacy-evaluation

 

 

 

 

 

 

Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hTIGIT mice. Mice were divided into control and treatment groups (n=5) when the tumor volume was about 150±50 mm3. The anti-human TIGIT antibody inhibits tumor growth in the homozygous B-hTIGIT mice, suggesting that the B-hTIGIT mouse model is an effective tool for in vivo hTIGIT antibody efficacy study. (A) Tumor average volume ±SEM, (B) Mice average weight ± SEM.

TIGIT Ab (Tiragolumab Analog) Efficacy Evaluation

B-hTIGIT-Mice-details-tigit-ab-tiragolumab-analog-efficacy-eval

 

 

 

 

 

 

TIGIT Ab (Tiragolumab Analog) efficacy evaluation experiment was performed with B-hTIGIT mice. Murine colon cancer MC38 cells were subcutaneously implanted into homozygous B-hTIGIT mice. Mice were divided into control and treatment groups (n = 6) when the tumor volume was about 150±50 mm3. The anti-human TIGIT antibody inhibits tumor growth in the homozygous B-hTIGIT mice, suggesting that the B-hTIGIT mouse model is an effective tool for in vivo hTIGIT antibody efficacy study. (A) Tumor average volume ± SEM, (B) Mice average weight ± SEM.

References

1. J Clin Invest. 2015 May;125(5):2046-58. doi:10.1172/JCI80445. Epub 2015 Apr 13.
2. Immunol Rev. 2017 Mar;276(1):112-120. doi:10.1111/imr.12518.
3. Cancer Cell. 2014 Dec 8;26(6):923-937. doi:10.1016/j.ccell.2014.10.018. Epub 2014 Nov 26.
4. J Exp Med. 2015 Nov 16;212(12):2165-82. doi:10.1084/jem.20150792. Epub 2015 Nov 9.

Back to top